Performance of the Tobacco, Alcohol, Prescription Medication, and Other Substance Use (TAPS) Tool for Substance Use Screening in Primary Care Patients
2016/09/05 by Jennifer McNeely, Li‐Tzy Wu, Li-Tzy Wu +17 · 28 citations
Medicine · #Substance Abuse Treatment and Outcomes #Opioid Use Disorder Treatment #Smoking Behavior and Cessation
paper · doi:10.7326/m16-0317
Abstract
BACKGROUND: Substance use, a leading cause of illness and death, is underidentified in medical practice. OBJECTIVE: The Tobacco, Alcohol, Prescription medication, and other Substance use (TAPS) tool was developed to address the need for a brief screening and assessment instrument that includes all commonly used substances and fits into clinical workflows. The goal of this study was to assess the performance of the TAPS tool in primary care patients. DESIGN: Multisite study, conducted within the National Drug Abuse Treatment Clinical Trials Network, comparing the TAPS tool with a reference standard measure. (ClinicalTrials.gov: NCT02110693). SETTING: 5 adult primary care clinics. PARTICIPANTS: 2000 adult patients consecutively recruited from clinic waiting areas. MEASUREMENTS: Interviewer- and self-administered versions of the TAPS tool were compared with a reference standard, the modified World Mental Health Composite International Diagnostic Interview (CIDI), which measures problem use and substance use disorder (SUD). RESULTS: Interviewer- and self-administered versions of the TAPS tool had similar diagnostic characteristics. For identifying problem use (at a cutoff of 1+), the TAPS tool had a sensitivity of 0.93 (95% CI, 0.90 to 0.95) and specificity of 0.87 (CI, 0.85 to 0.89) for tobacco and a sensitivity of 0.74 (CI, 0.70 to 0.78) and specificity of 0.79 (CI, 0.76 to 0.81) for alcohol. For problem use of illicit and prescription drugs, sensitivity ranged from 0.82 (CI, 0.76 to 0.87) for marijuana to 0.63 (CI, 0.47 to 0.78) for sedatives; specificity was 0.93 or higher. For identifying any SUD (at a cutoff of 2+), sensitivity was lower. LIMITATIONS: The low prevalence of some drug classes led to poor precision in some estimates. Research assistants were not blinded to participants' TAPS tool responses when they administered the CIDI. CONCLUSION: In a diverse population of adult primary care patients, the TAPS tool detected clinically relevant problem substance use. Although it also may detect tobacco, alcohol, and marijuana use disorders, further refinement is needed before it can be recommended broadly for SUD screening. PRIMARY FUNDING SOURCE: National Institute on Drug Abuse.
Citations
Cited by
- Preventive care recommendations to promote health equity
- MoMA: A Mixture-of-Multimodal-Agents Architecture for Enhancing Clinical Prediction Modelling
- Dental Screening, Counseling, and Referral to Treatment for Substance Use Disorder: Survey of the National Dental Practice-Based Research Network
- Validation of the TAPS-1: A Four-Item Screening Tool to Identify Unhealthy Substance Use in Primary Care. [europepmc]
- DSM-5 substance use disorders among adult primary care patients: Results from a multisite study. [europepmc]
- Screening for Behavioral Health Conditions in Primary Care Settings: A Systematic Review of the Literature. [europepmc]
- Prevalence, patterns, and correlates of multiple substance use disorders among adult primary care patients. [europepmc]
- A Quality Framework for Emergency Department Treatment of Opioid Use Disorder. [europepmc]
- Screening for Substance Use in Rural Primary Care: a Qualitative Study of Providers and Patients. [europepmc]
- Electronic self-administered screening for substance use in adult primary care patients: feasibility and acceptability of the tobacco, alcohol, prescription medication, and other substance use (myTAPS) screening tool. [europepmc]
- Integrating Treatment for Co-Occurring Mental Health Conditions. [europepmc]
- Prevalence and treatment of opioid use disorders among primary care patients in six health systems. [europepmc]
- Prevalence of documented alcohol and opioid use disorder diagnoses and treatments in a regional primary care practice-based research network. [europepmc]
- Routine Assessment of Symptoms of Substance Use Disorders in Primary Care: Prevalence and Severity of Reported Symptoms. [europepmc]
- Validation of the NIDA-modified ASSIST as a Screening Tool for Prenatal Drug Use in an Urban Setting in the United States. [europepmc]
- Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders. [europepmc]
- Documented opioid use disorder and its treatment in primary care patients across six U.S. health systems. [europepmc]
- The Opioid-overdose Reduction Continuum of Care Approach (ORCCA): Evidence-based practices in the HEALing Communities Study. [europepmc]
- Developing an Adaptive Mobile Intervention to Address Risky Substance Use Among Adolescents and Emerging Adults: Usability Study. [europepmc]
- The disparate impact of COVID-19 on the mental health of female and male caregivers. [europepmc]
- Is telemedicine the answer to rural expansion of medication treatment for opioid use disorder? Early experiences in the feasibility study phase of a National Drug Abuse Treatment Clinical Trials Network Trial. [europepmc]
- Trends and correlates of cocaine use among adults in the United States, 2006-2019. [europepmc]
- Comparison of Methods for Alcohol and Drug Screening in Primary Care Clinics. [europepmc]
- Home-based virtual reality for chronic pain: protocol for an NIH-supported randomised-controlled trial. [europepmc]
- Management of opioid use disorder and associated conditions among hospitalized adults: A Consensus Statement from the Society of Hospital Medicine. [europepmc]
- Validity of the Single-Item Screen-Cannabis (SIS-C) for Cannabis Use Disorder Screening in Routine Care. [europepmc]
- CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022. [europepmc]
- Substance use disorders: a comprehensive update of classification, epidemiology, neurobiology, clinical aspects, treatment and prevention. [europepmc]
Related